<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291823</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH10</org_study_id>
    <nct_id>NCT01291823</nct_id>
  </id_info>
  <brief_title>Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer</brief_title>
  <official_title>A Phase II Study of Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over
      30 fractions, and concurrent with Gefitinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: to evaluate the efficacy and toxicity of a concomitant treatment using EGFR-TKI and
      thoracic radiation in elderly patients with esophageal Cancer.

      Methods:Patients(&gt;70 years old) with esophageal Cancer will receive thoracic radiation
      therapy 54-60 Gy over 30 fractions and concurrent with gefitinib 250mg/day.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>1 month after the thoracic radiotherapy and concurrent gefitinib treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety (The safety was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0.)</measure>
    <time_frame>1 month after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Concomitant Gefitinib and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received Gefitinib and radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>gefitinib 250mg/day</description>
    <arm_group_label>Concomitant Gefitinib and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic radiotherapy</intervention_name>
    <description>Thoracic radiotherapy 54-60Gy over 30 fraction</description>
    <arm_group_label>Concomitant Gefitinib and radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented diagnosis of esophageal Cancer

          -  Disease must be encompassed in a radiotherapy field.Patients with celiac, perigastric,
             mediastinal or supraclavicular adenopathy are eligible

          -  age:70-85 years

          -  Written informed consent.

          -  Performance status of 0 to 2

          -  Neutrophil count &gt;1.5 x 10 to the 9th power/L and platelets &gt; 100 x 10 to the 9th
             power/L.

          -  Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN)
             Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5
             times ULN (or less than or equal to 5 times ULN in case of known liver involvement

          -  Renal: Serum Creatinine less than or equal to 1.5 times upper limit of normal (ULN)

        Exclusion Criteria:

          -  Evidence of tracheoesophageal fistula, or invasion into the trachea or major bronchi.

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity,
             or cervix are all permissible).

          -  Prior systemic chemotherapy or radiation therapy for esophageal cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mao Weimin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xu yaping, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>0086-571-88122082</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mao Weimin, MD</last_name>
    <phone>0086-571-88122222</phone>
    <email>maowmzj1218@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xu Yaping, MD</last_name>
    <phone>0086-571-88122082</phone>
    <email>xuyaping1207@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu yaping, MD</last_name>
      <phone>0086-571-88122</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>February 7, 2011</last_update_submitted>
  <last_update_submitted_qc>February 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>MAO Weiminï¼ŒXU Yaping</name_title>
    <organization>Zhejiang Cancer Hospital</organization>
  </responsible_party>
  <keyword>gefitinib</keyword>
  <keyword>radiation</keyword>
  <keyword>esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

